BR112015023404A2 - sequestrantes de precursores de produto final de glicação avançada (age) - Google Patents

sequestrantes de precursores de produto final de glicação avançada (age)

Info

Publication number
BR112015023404A2
BR112015023404A2 BR112015023404A BR112015023404A BR112015023404A2 BR 112015023404 A2 BR112015023404 A2 BR 112015023404A2 BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A2 BR112015023404 A2 BR 112015023404A2
Authority
BR
Brazil
Prior art keywords
age
sequestrants
precursor
end product
advanced glycation
Prior art date
Application number
BR112015023404A
Other languages
English (en)
Other versions
BR112015023404A8 (pt
Inventor
T Papoulis Andrew
Besev Magnus
Dhal Pradeep
J Miller Robert
Randall Holmes-Farley Stephen
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015023404A2 publication Critical patent/BR112015023404A2/pt
Publication of BR112015023404A8 publication Critical patent/BR112015023404A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo patente de invenção: "sequestrantes de precursores de produto final de glicação avançada (age)". trata-se de sequestrantes de precursores de age que compreendem aminas separadas por 2, 3 ou 4 carbonos. os sequestrantes de precursores de age podem ser usados como agentes farmacêuticos e em composições farmacêuticas. os sequestrantes de precursores de age são úteis, em particular, ligando precursores de age e dicarbonilas alimentares em mamíferos no trato gastrointestinal para o tratamento de indisposições como neuropatia diabética, doença renal crônica, aterosclerose, derrame, catarata e doença de alzheimer.
BR112015023404A 2013-03-15 2014-03-12 composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos BR112015023404A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (2)

Publication Number Publication Date
BR112015023404A2 true BR112015023404A2 (pt) 2017-07-18
BR112015023404A8 BR112015023404A8 (pt) 2019-12-03

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023404A BR112015023404A8 (pt) 2013-03-15 2014-03-12 composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos

Country Status (24)

Country Link
US (2) US20160024233A1 (pt)
EP (1) EP2968403A1 (pt)
JP (4) JP2016512830A (pt)
KR (1) KR20150130492A (pt)
CN (1) CN105188718A (pt)
AR (1) AR095593A1 (pt)
AU (2) AU2014235500A1 (pt)
BR (1) BR112015023404A8 (pt)
CA (1) CA2906501A1 (pt)
CL (1) CL2015002624A1 (pt)
CR (1) CR20150545A (pt)
DO (1) DOP2015000221A (pt)
EA (1) EA201591733A1 (pt)
HK (1) HK1220607A1 (pt)
IL (1) IL241406A0 (pt)
MA (1) MA38487A1 (pt)
MX (1) MX2015012843A (pt)
PE (1) PE20151766A1 (pt)
PH (1) PH12015502019A1 (pt)
SG (2) SG10201707590XA (pt)
TN (1) TN2015000390A1 (pt)
TW (1) TW201521744A (pt)
UY (1) UY35441A (pt)
WO (1) WO2014150873A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
RU2020111589A (ru) * 2017-08-31 2021-09-30 Сайтосорбентс Корпорейшн Снижение уровня конечных продуктов глубокого гликирования из биологических жидкостей

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
WO2005032563A1 (en) * 2003-09-02 2005-04-14 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
WO2005079463A2 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US9181364B2 (en) * 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
JP2016512830A (ja) 2016-05-09
TN2015000390A1 (en) 2017-01-03
PE20151766A1 (es) 2015-12-11
DOP2015000221A (es) 2015-12-15
AR095593A1 (es) 2015-10-28
WO2014150873A1 (en) 2014-09-25
JP2018135365A (ja) 2018-08-30
UY35441A (es) 2014-10-31
CA2906501A1 (en) 2014-09-25
JP2020055850A (ja) 2020-04-09
US20160024233A1 (en) 2016-01-28
SG10201707590XA (en) 2017-11-29
US20180265613A1 (en) 2018-09-20
MX2015012843A (es) 2016-08-08
CL2015002624A1 (es) 2016-03-11
EA201591733A1 (ru) 2016-01-29
IL241406A0 (en) 2015-11-30
AU2014235500A1 (en) 2015-11-05
AU2019201259A1 (en) 2019-03-14
CN105188718A (zh) 2015-12-23
EP2968403A1 (en) 2016-01-20
BR112015023404A8 (pt) 2019-12-03
PH12015502019A1 (en) 2016-01-11
HK1220607A1 (zh) 2017-05-12
SG11201506413PA (en) 2015-09-29
MA38487A1 (fr) 2017-12-29
KR20150130492A (ko) 2015-11-23
TW201521744A (zh) 2015-06-16
CR20150545A (es) 2015-12-01
JP2022037143A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
PH12015502275B1 (en) Therapuetic uses of empagliflozin
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
BR112015014372A2 (pt) inibidores de autotaxina
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
BR112015000582A2 (pt) método, e composição
BR112016007536A8 (pt) compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX340985B (es) Compuestos de n-heteroarilo.
EA201500294A1 (ru) Ноотропные композиции для улучшения свойств памяти
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
FR2954945B1 (fr) Composition cosmetique ou dermatologique, procede de traitement cosmetique et derive d'acide hyaluronique
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
BR112016014615A2 (pt) Um pó de carbono condutivo, um método para a manufaturação do mesmo e utilização do mesmo
RS53457B (en) COMPOSITION AND ITS APPLICATION IN THE TREATMENT OF ANAL RAGAD
BR112015009816A2 (pt) composições de moldagem e sobremoldagem para dispositivos eletrônicos
BR112015023404A2 (pt) sequestrantes de precursores de produto final de glicação avançada (age)
WO2017079403A3 (en) Polymeric nanoparticles
EA201501177A1 (ru) Фармацевтические композиции
BR112015019084A2 (pt) métodos para aumentar o rendimento das culturas
EA201590782A1 (ru) Оксирановые амины

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements